Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Function of Renal Transplant Clear all
Recruiting Phase 4 Interventional

Randomized Trial of SGLT2i in Heart Transplant Recipients

NCT06625073
View directory record Official record
Conditions
Heart Transplant, Cardiovascular Disease, Kidney Disease
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Palo Alto, California • Nashville, Tennessee • Houston, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 23, 2026, 6:27 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant

NCT02490202
View directory record Official record
Conditions
Delayed Function of Renal Transplant
Interventions
SANGUINATE, Normal Saline
Drug
Lead sponsor
Prolong Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Jul 23, 2026, 6:27 PM EDT
Completed No phase listed Observational

Studies of Organ Transplantation in Animals and Man

NCT00156364
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Michael Mauer, MD
Individual
Eligibility
18 Years to 60 Years
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1981 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Jul 23, 2026, 6:27 PM EDT
Completed No phase listed Observational

A Study of Factors That Affect Long-Term Kidney Transplant Function

NCT00270712
View directory record Official record
Conditions
Kidney Transplant
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
3,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
5
States / cities
Birmingham, Alabama • Iowa City, Iowa • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Jul 23, 2026, 6:27 PM EDT
Completed Not applicable Interventional

Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern in Kidney Transplant Recipients

NCT01093703
View directory record Official record
Conditions
Blood Pressure Control, Kidney Transplant Recipient
Interventions
Medication Adjustment
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Jul 23, 2026, 6:27 PM EDT
Completed Phase 3 Interventional Results available

Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients

NCT02192502
View directory record Official record
Conditions
Postoperative Kidney Injury
Interventions
human albumin 5%, HES 130/0.4 (Voluven)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 85 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Jul 23, 2026, 6:27 PM EDT
Completed Not applicable Interventional

Non-Invasive Evaluation of Transplant Kidney Using OCT

NCT02084966
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Procedure/Surgery: Transplantation: OCT of Kidney Transplant
Procedure
Lead sponsor
Georgetown University
Other
Eligibility
Not listed
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Jul 23, 2026, 6:27 PM EDT
Completed Not applicable Interventional Results available

Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

NCT01936519
View directory record Official record
Conditions
Immunosuppression, Renal Failure
Interventions
Arm A: Everolimus, Calcineurin Inhibitor
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Jul 23, 2026, 6:27 PM EDT
Completed Phase 3 Interventional

Remote Ischemic Preconditioning In Abdominal Organ Transplantation

NCT00975702
View directory record Official record
Conditions
Kidney Disease, Liver Disease, Pancreas Disease
Interventions
RIPC by Inflation of Pneumatic Tourniquet
Procedure
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
5 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Jul 23, 2026, 6:27 PM EDT
Recruiting No phase listed Observational

Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection

NCT05084768
View directory record Official record
Conditions
Acute Rejection of Renal Transplant, Graft Failure
Interventions
Donor-derived cell-free DNA
Diagnostic Test
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 23, 2026, 6:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Prospective Evaluation of Pancreatic Function in Pancreas Transplant Recipients

NCT00571818
View directory record Official record
Conditions
Transplant, Diabetes
Interventions
Oral glucose tolerance test, IV Glucose Tolerance Test
Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 23, 2026, 6:27 PM EDT
Completed Phase 4 Interventional Results available

Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant

NCT00118742
View directory record Official record
Conditions
Liver Transplantation
Interventions
mycophenolate mofetil [CellCept], Tacrolimus, Cyclosporine, Sirolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 74 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2010 · Synced Jul 23, 2026, 6:27 PM EDT
Not listed Phase 4 Interventional

A Study of Thymoglobulin and Tacrolimus in Liver Transplant

NCT00564538
View directory record Official record
Conditions
Liver Transplantation, Liver Disease, Immunosuppression
Interventions
anti-thymocyte globulin (rabbit), tacrolimus
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 27, 2007 · Synced Jul 23, 2026, 6:27 PM EDT
Terminated Phase 4 Interventional

Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients

NCT00121784
View directory record Official record
Conditions
Heart Transplantation
Interventions
mycophenolate mofetil [CellCept]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
11
States / cities
Chicago, Illinois • Maywood, Illinois • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 6:27 PM EDT
Recruiting Phase 4 Interventional

Effect of Alkali Therapy on Vascular and Graft Function in Kidney Transplant Recipients

NCT05005793
View directory record Official record
Conditions
Metabolic Acidosis, Kidney Transplant; Complications, Vascular Diseases
Interventions
Sodium bicarbonate, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jul 23, 2026, 6:27 PM EDT
Recruiting Phase 4 Interventional

Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients

NCT06140537
View directory record Official record
Conditions
Kidney Transplant; Complications, Vascular Diseases, Diabetes
Interventions
Dapagliflozin 10mg Tab, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jul 23, 2026, 6:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

NCT00622869
View directory record Official record
Conditions
Liver Transplantation
Interventions
Tacrolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Everolimus (reduced tacrolimus), Everolimus (tacrolimus elimination), Corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Jul 23, 2026, 6:27 PM EDT
Not listed Phase 3 Interventional

Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study

NCT01067950
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Isolated Pancreas Transplant, Intensive Insulin Therapy
Procedure · Drug
Lead sponsor
Nantes University Hospital
Other
Eligibility
25 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2010 · Synced Jul 23, 2026, 6:27 PM EDT
Completed Phase 2 Interventional Results available

Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation

NCT00248040
View directory record Official record
Conditions
Ischemia-Reperfusion Injury, Kidney Diseases
Interventions
Reparixin continuous infusion, reparixin intermittent infusion, placebo infusion
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Jul 23, 2026, 6:27 PM EDT
Completed Phase 3 Interventional

A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients

NCT00048152
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Corticosteroids, Neoral, Zenapax, mycophenolate mofetil [CellCept]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 6:27 PM EDT
Completed Not applicable Interventional

Physical Activity Program for Older Renal Transplant Candidates

NCT00857974
View directory record Official record
Conditions
Renal Transplant Candidate
Interventions
Physical Activity
Other
Lead sponsor
Wake Forest University
Other
Eligibility
60 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Jul 23, 2026, 6:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

NCT01544491
View directory record Official record
Conditions
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Interventions
RAD001, MMF
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Jul 23, 2026, 6:27 PM EDT
Completed Phase 4 Interventional Results available

Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

NCT00369382
View directory record Official record
Conditions
Graft Rejection, Kidney Failure
Interventions
cyclosporine or tacrolimus, sirolimus
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
8
States / cities
Tampa, Florida • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Jul 23, 2026, 6:27 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

NCT01150097
View directory record Official record
Conditions
Liver Transplant Recipient
Interventions
Tacrolimus (reduced tacrolimus), Everolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Everolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
20 Years to 75 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Lexington, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Jul 23, 2026, 6:27 PM EDT